In consumer tech, iteration is the rule. New chips come out. Batteries last longer. Cameras get sharper. People upgrade with a swipe of a card and a recycled box. That logic doesn't map to invasive neurotechnology. Not even close.
You don’t walk into a clinic, unplug your old brain implant, and walk out with a new one over lunch. And yet, as companies in this space develop better hardware at a faster pace, the question becomes more urgent: What does it actually mean to upgrade a device that lives inside your brain?
The Problem
The fundamental problem is biological permanence. Neural implants, whether cortical arrays, deep brain stimulators, or bidirectional BCIs, are invasive by nature. They’re designed to sit in the body for years, sometimes decades. That makes them medical infrastructure, not consumer products.
Every implant, no matter how small, involves some degree of surgical risk. The body doesn’t always welcome revision. Scar tissue may form around the implant. Bone heals. The brain shifts. Every upgrade introduces the possibility of disrupting something that was already working.
Even if the new version is objectively better, featuring more channels, faster sampling, and improved power delivery, the upgrade path is nontrivial. It involves:
A second neurosurgery
Device explant and reimplant logistics
Changes to external systems and user interfaces
New clinical training protocols
Updated FDA (or international) approvals
No matter how elegant the engineering, the stakes are different when your hardware touches neurons. Companies can’t assume users will (or should) upgrade just because the tech improved.
What Are the Options?
There are three main strategies companies use to address this:
Design for LongevitySome teams choose to slow down the hardware iteration cycle and instead focus on making each version last as long as possible. This means robust materials, fail-safes, and conservative upgrades that reduce the need for explantation. Think of it as the pacemaker model—10 to 15 years per device.
Design for ModularityOthers are trying to make part of the system upgradeable. For example, keep the implanted electrodes in place but allow the signal processor or telemetry unit to be detached and replaced. In theory, this reduces the need for repeat surgery and allows software and hardware to evolve independently. It’s an elegant idea, but harder to execute than it sounds. Connectors need to remain viable in the body for years, and that interface between biology and plastic is rarely stable over long timescales.
Design for RedeploymentSome teams are betting that reimplantation will be safe and routine enough to justify replacement after a few years. If the benefits outweigh the surgical risk, and if that risk is lowered by surgical robotics and better procedural protocols, then perhaps upgrades will become more common. In this case, the key is not to avoid reimplantation, but to make it worth it.
What Are Companies Doing Today?
Different companies are taking different paths:
Neuralink is leaning heavily into robotic precision to reduce the invasiveness and risk of implantation. Their pitch seems to imply that reimplantation will become straightforward enough that users can receive newer versions over time, especially as signal quality and channel count improve.
Synchron, which uses a much less invasive endovascular approach, may not be thinking about upgrades in the same way. Their stentrode design focuses on safety, stability, and patient comfort. Long-term durability takes precedence over iterative speed.
Blackrock Neurotech and Paradromics, which use penetrating electrodes for high-bandwidth BCI, face the more traditional clinical neurosurgery workflow. For them, the upgrade equation is tied to partnerships with hospitals and the predictability of explant/reimplant procedures.
Internally, most of these companies build out support teams to monitor patients over time. They gather signal quality data, track decline, and only suggest upgrades when the benefit is clear. This makes the upgrade question less about feature parity and more about clinical relevance.
How Is This Communicated to Users?
Carefully. Often, not at all—at least not in marketing copy.
For patients in trials or early commercial deployments, upgrade decisions are discussed within a clinical context. Physicians walk them through risks and benefits. There's consent, follow-up, and often second opinions. It’s not framed like buying a new device. It’s framed like deciding to get another surgery.
Externally, companies tend to emphasize progress and iteration in public materials, but they rarely speak about upgrade paths explicitly. That’s not just branding—it’s legal and ethical caution. No company wants to suggest that today’s implant will be obsolete in two years. That kind of messaging introduces uncertainty and fear, especially for patients who already committed to an earlier model.
The result is a tension: rapid iteration internally, slow replacement externally. Companies develop faster than patients can—or should—adopt.
Why It Matters
This isn’t just a logistics issue. It’s a UX issue. It’s a trust issue. It’s a systems design issue.
If the industry wants brain interfaces to scale, it must get better at managing time. Not just time to market, but time in body. It must design for upgradeability without assuming it. It must build modularity into both the technical stack and the clinical relationships.
Getting a new neural chip is not like getting a new iPhone. It never will be. It’s more like choosing a new organ. A quieter one. One that doesn’t beat or filter blood, but listens.
That kind of upgrade should feel less like a product launch and more like a promise.
Until next time,
—Daniel